New York Genome Center, Inc.

New York Genome Center, Inc., doing business as Nygc, is a nonprofit academic research institution headquartered in New York that delivers next-generation sequencing, whole genome sequencing, RNA sequencing, and related genomic characterization services to the federal government as a prime contractor on research and development grants and contracts (57% of recent awards) and as a subcontractor on grants with academic prime recipients (43% of awards). The vendor competes predominantly in full-and-open federal procurements with no set-aside designations across its federal portfolio.

Nygc's customer concentration is heavily concentrated in the National Institutes of Health, which funds the overwhelming majority of its work. The National Heart, Lung and Blood Institute anchors the largest single dollar commitment: a $500 million single-award Indefinite Delivery Contract for Trans-Omics for Precision Medicine (TOPMed) Centralized Omics Resource services, awarded September 14, 2023, with completion targeted for September 13, 2033. Under this IDV, Nhlbi has issued three delivery orders totaling approximately $10.4 million to date, including a $7.0 million firm fixed-price RNA-sequencing task order awarded September 23, 2024, and a $3.7 million delivery order for centralized omics resource core services awarded September 23, 2025. The National Cancer Institute is the second-largest customer by award count (27 awards, $199.5 million combined potential value), with Nygc holding a $149.2 million Genomic Characterization Centers indefinite-delivery contract awarded January 13, 2025, running through January 12, 2030. The National Institute on Drug Abuse issued a $149 million Indefinite Delivery contract for the BRAIN Initiative Cell Atlas Network (BICAN) Sequencing Core, awarded January 31, 2023, with a $73.8 million task order for BICAN sequencing services. The National Institute of Mental Health has issued 9 awards totaling $149 million combined potential value. The Department of Veterans Affairs' Veterans Integrated Service Network 2 operates as a recurring smaller customer (13 awards, $1.1 million combined potential value) for next-generation sequencing supporting ongoing research studies.

Nygc's prime contract vehicles include the $500 million TOPMed IDIQ with NHLBI, the $149.2 million NCI Genomic Characterization Centers IDIQ, and the $149 million BICAN Sequencing Core IDIQ with NIDA. A single-award indefinite-delivery contract with Veterans Integrated Service Network 2 (ceiling $356,920) has issued four delivery orders for next-generation sequencing services through May 31, 2027.

Activity has grown year over year, from 10 awards in 2022 to 27 in 2024, with 18 awards in 2025 and 9 year-to-date in 2026. Thirteen awards with combined potential value of $81.3 million reach ultimate completion within the next twenty-four months, presenting recompete exposure concentrated in NHLBI and NIDA vehicle renewals.

Nygc acts predominantly as a prime on its federal work, with minimal subcontractor engagement on SCI-reportable service contracts. The SCI dataset shows $10 million in invoiced revenue across FY2022–FY2024, with federal services activity concentrated in FY2024 (nine contracts, $9.8 million across 130 FTEs). Government-paid hourly rates on prime contracts ranged from a 10th percentile of $10.73/hr to a 90th percentile of $530.26/hr, with a median around $25.62/hr, reflecting a mix of sequencing operations labor and senior scientific and computational biology staff. SCI-reportable sub-hours share across prime contracts was zero percent, indicating that Nygc delivers its services through its own workforce rather than routing work to subcontractors.

Nygc operates as a prime recipient on a substantial federal grant portfolio, with primary funding from the National Cancer Institute, National Human Genome Research Institute, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of General Medical Sciences, National Heart Lung and Blood Institute, and the National Science Foundation. Representative grants include a $270,683 National Cancer Institute Cancer Biology Research award (CFDA 93.396) for development and validation of Paired-Break-Seq, a single-cell multiomics sequencing technique (May 5, 2026); a $1.737 million National Institute of General Medical Sciences Biomedical Research award (CFDA 93.859) supporting single-cell genomics technologies for joint analysis of regulatory dynamics (September 1, 2023); a $784,000 Eunice Kennedy Shriver National Institute of Child Health and Human Development Cooperative Agreement (CFDA 93.865) for statistical methods development on the Developmental GTEx project (September 24, 2024); a $319,753 National Science Foundation Technology, Innovation, and Partnerships Phase I award (CFDA 47.084) to establish an open-source ecosystem for repurposing decommissioned DNA sequencers as automation platforms (July 15, 2025); and a $1.737 million Somatic Mosaicism Across Human Tissues (SmaHT) Cooperative Agreement (May 1, 2023) led by the Office of the Director. Nygc acts as a sub-recipient on numerous grants from Columbia University, Weill Cornell Medicine, the Broad Institute, Icahn School of Medicine at Mount Sinai, Princeton University, and the Salk Institute, performing high-throughput genomic sequencing, single-cell multiomics analysis, RNA sequencing, spatial transcriptomics, CRISPR screens, and bioinformatics support. The sub-award footprint shows consistent engagement with Columbia University (15+ sub-awards since 2021), Weill Cornell Medicine (12+ sub-awards), and the Broad Institute (3+ sub-awards) on multi-year research initiatives spanning cancer genomics, neuropsychiatric disease, developmental biology, and precision medicine.

Nygc's business is concentrated on advanced genomic sequencing services, computational biology, and single-cell multiomics technology development in support of federal biomedical research. All work is performed at its New York, New York headquarters.